A 58-year-old man from Delhi presents with progressive dyspnea on exertion for 3 months, orthopnea, and bilateral ankle edema. He has a history of hypertension (BP 160/100 mmHg today) and type 2 diabetes. On examination, JVP is elevated at 8 cm, S3 gallop is audible, and fine crackles are heard at both lung bases. Chest X-ray shows cardiomegaly and bilateral pulmonary edema. Echocardiography reveals LVEF 35%, global hypokinesis, and LV end-diastolic dimension 62 mm. Which of the following is the most appropriate initial pharmacological intervention?

Question

Accepted Answer

D. Lisinopril 5 mg once daily + Carvedilol 3.125 mg twice daily. ## Clinical Diagnosis

This patient presents with **symptomatic systolic heart failure (HF)** with reduced ejection fraction (HFrEF):
- LVEF 35% (< 40% = HFrEF)
- Signs of pulmonary congestion (orthopnea, crackles, cardiomegaly on CXR)
- Signs of systemic congestion (elevated JVP, ankle edema)
- S3 gallop (hallmark of HF)

## Guideline-Based Initial Therapy

**Key Point:** In symptomatic HFrEF, the cornerstone of therapy is **dual initiation** of an ACE inhibitor (or ARB) AND a beta-blocker, both of which have proven mortality benefit and are Class I recommendations in major guidelines (ACC/AHA, ESC, CSCI).

### Why ACE-I + Beta-Blocker?

| Drug Class | Mechanism | Mortality Benefit | Timing |
|---|---|---|---|
| ACE Inhibitor | Blocks RAAS, reduces afterload, prevents remodeling | Yes (landmark: SOLVD, CONSENSUS) | Start early, uptitrate |
| Beta-Blocker | Reduces sympathetic drive, improves diastolic function, anti-arrhythmic | Yes (landmark: CIBIS, MERIT-HF, COPERNICUS) | Start low, uptitrate |
| Diuretic | Relieves congestion | No mortality benefit | Symptom relief only |
| Aldosterone Antagonist | RAAS inhibition, K+ retention | Yes (landmark: RALES) | Add after ACE-I/BB established |

**High-Yield:** The sequence is ACE-I/ARB → Beta-blocker → Diuretic (for symptoms) → Aldosterone antagonist (if LVEF ≤ 35% and tolerated). Do NOT start with diuretics alone or digoxin as monotherapy.

## Explanation of Correct Answer (Option 1)

**Lisinopril 5 mg daily + Carvedilol 3.125 mg BD:**
- **Lisinopril** = ACE inhibitor; starting dose is appropriate
- **Carvedilol** = beta-blocker with alpha-blocking properties; starting dose is low and safe
- Both are Class I recommendations for HFrEF
- Both are uptitrated based on tolerance (target: Lisinopril 10 mg daily, Carvedilol 25 mg BD)
- This combination addresses the underlying pathophysiology (RAAS + sympathetic overactivation)

**Clinical Pearl:** In Indian patients with HFrEF, ACE-I is preferred over ARB as first-line unless contraindicated (cough, angioedema). Carvedilol is preferred over metoprolol or atenolol in HFrEF due to superior outcomes in the COPERNICUS trial.

## Why Diuretics Are NOT First-Line

While this patient has clear signs of congestion (orthopnea, edema, crackles), **diuretics do NOT reduce mortality** — they only relieve symptoms. Starting with furosemide + spironolactone (Option 2) would be premature without first establishing ACE-I/BB therapy.

## Why Other Options Are Suboptimal

**Option 3 (Nitrate + Hydralazine):** This combination has a role in:
- HF with preserved ejection fraction (HFpEF) in specific populations
- Patients with ACE-I/ARB intolerance
- It does NOT replace ACE-I/BB in HFrEF; mortality benefit is inferior to RAAS inhibition

**Option 4 (Digoxin + Chlorthalidone):** 
- Digoxin has NO mortality benefit in HF; it only reduces symptoms and hospitalizations
- Chlorthalidone is a thiazide diuretic; diuretics alone do not address the underlying pathophysiology
- This approach is outdated and not guideline-concordant for initial therapy

**Mnemonic for HFrEF Initial Therapy:** **"ACE-BB-DAAD"**
- **A**CE inhibitor
- **C**arvedilol (or other beta-blocker)
- **E**veryone gets these two first
- **B**eta-blocker
- **D**iuretic (if congestion)
- **A**ldosterone antagonist (if LVEF ≤ 35%)
- **A**rni (sacubitril/valsartan, if tolerated, replaces ACE-I)
- **D**apagliflozin or empagliflozin (SGLT2i, now Class IIa for all HFrEF)

Answer

A. Furosemide 40 mg twice daily + Spironolactone 25 mg once daily

Answer

B. Isosorbide dinitrate 10 mg thrice daily + Hydralazine 25 mg thrice daily

Answer

C. Digoxin 0.25 mg once daily + Chlorthalidone 25 mg once daily

Explanation

Clinical Diagnosis

Guideline-Based Initial Therapy

Why ACE-I + Beta-Blocker?

Explanation of Correct Answer (Option 1)

Why Diuretics Are NOT First-Line

Why Other Options Are Suboptimal

Practice similar questions

Join our NEET PG community

Drug Class	Mechanism	Mortality Benefit	Timing
ACE Inhibitor	Blocks RAAS, reduces afterload, prevents remodeling	Yes (landmark: SOLVD, CONSENSUS)	Start early, uptitrate
Beta-Blocker	Reduces sympathetic drive, improves diastolic function, anti-arrhythmic	Yes (landmark: CIBIS, MERIT-HF, COPERNICUS)	Start low, uptitrate
Diuretic	Relieves congestion	No mortality benefit	Symptom relief only
Aldosterone Antagonist	RAAS inhibition, K+ retention	Yes (landmark: RALES)	Add after ACE-I/BB established